Autoimmune cytopenia is a general term for all hemocytopenia diseases caused by humoral or cellular immunity abnormalities, and its common immune mechanism determines the importance of immunosuppressive therapy. Sirolimus, as an immunosuppressant against of mTOR, induces immune tolerance by adjusting Treg cells, which has application prospect in the treatment of refractory autoimmune cytopenia. This article reviews the mechanism, application, and possible adverse reactions of sirolimus in the treatment of idiopathic autoimmune cytopenia.
题目: 西罗莫司治疗原发性免疫性血细胞减少症的研究进展.
摘要: 免疫性血细胞减少症是对所有体液或细胞免疫异常导致的血细胞减少性疾病的总称，其共同免疫机制决定了免疫抑制治疗的重要性。西罗莫司作为针对哺乳动物雷帕霉素靶蛋白的免疫抑制剂，通过调整Treg细胞诱导免疫耐受，在难治性免疫性血细胞减少症中具有应用前景。本文主要就西罗莫司在原发性免疫性血细胞减少症治疗中的作用机制、应用进展及可能的不良反应进行综述。.